Raul Torres-Ruiz

List of Publications by Year in Descending Order

54 papers	1,375 citations	19 h-index	36 g-index
62 ext. papers	1,805 ext. citations	8.6 avg, IF	4.3 L-index

#	Paper	IF	Citations
54	CRISPR Approaches for the Diagnosis of Human Diseases.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	1
53	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.. *EMBO Molecular Medicine*, **2022**, e14552	12	2
52	A faecal microbiota signature with high specificity for pancreatic cancer.. *Gut*, **2022**,	19.2	5
51	Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism.. *Nature Cancer*, **2021**, 2, 1387-1405	15.4	7
50	Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. *Nature Communications*, **2021**, 12, 6910	17.4	6
49	Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects. *Scientific Reports*, **2021**, 11, 3490	4.9	4
48	PD-L1 expression in peripheral T-cell lymphomas is not related to either gene amplification or rearrangements. *Leukemia and Lymphoma*, **2021**, 62, 1648-1656	1.9	2
47	Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	1
46	Detection of chromosome instability by interphase FISH in mouse and human tissues. *STAR Protocols*, **2021**, 2, 100631	1.4	0
45	Analysis of Telomere Maintenance Related Genes Reveals as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. *Cancers*, **2021**, 13,	6.6	2
44	A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. *Molecular Therapy*, **2021**,	11.7	6
43	and Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9. *Molecular Therapy - Methods and Clinical Development*, **2020**, 19, 426-437	6.4	1
42	RIAM-VASP Module Relays Integrin Complement Receptors in Outside-In Signaling Driving Particle Engulfment. *Cells*, **2020**, 9,	7.9	4
41	Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells. *Molecular Therapy - Nucleic Acids*, **2020**, 20, 196-204	10.7	4
40	The value of lncRNAFENDRRandFOXF1as a prognostic factor for survival of lung adenocarcinoma. *Oncotarget*, **2020**, 11, 1172-1185	3.3	8
39	The value of lncRNA and as a prognostic factor for survival of lung adenocarcinoma. *Oncotarget*, **2020**, 11, 1172-1185	3.3	8
38	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. *Nature Communications*, **2020**, 11, 5060	17.4	22

37	Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human Expression. *Frontiers in Genetics*, **2020**, 11, 552949	4.5	
36	Targeting OGG1 arrests cancer cell proliferation by inducing replication stress. *Nucleic Acids Research*, **2020**, 48, 12234-12251	20.1	8
35	Fast Diffusion Sustains Plasma Membrane Accumulation of Phosphatase of Regenerating Liver-1. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 585842	5.7	3
34	NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. *Cell Stem Cell*, **2019**, 25, 607-621.e7	18	33
33	Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between and fusions. *Haematologica*, **2019**, 104, 1189-1201	6.6	12
32	Functional characterization of two enhancers located downstream FOXP2. *BMC Medical Genetics*, **2019**, 20, 65	2.1	4
31	Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing. *Molecular Therapy*, **2019**, 27, 986-998	11.7	48
30	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. *Cancer Immunology Research*, **2019**, 7, 644-657	12.5	52
29	Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity. *Oncogene*, **2019**, 38, 6226-6239	9.2	13
28	Gene editing of PKLR gene in human hematopoietic progenitors through 5Rand 3RUTR modified TALEN mRNA. *PLoS ONE*, **2019**, 14, e0223775	3.7	15
27	NHEJ-Mediated Gene Editing, a Versatile Approach to Correct a Variety of Fanconi Anemia Genes in HSCs. *Blood*, **2019**, 134, 4639-4639	2.2	
26	NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. *Leukemia*, **2019**, 33, 1557-1569	10.7	22
25	Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. *Nature Communications*, **2018**, 9, 1466	17.4	38
24	mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. *Cell Metabolism*, **2018**, 27, 118-135.e8	24.6	26
23	Narrowing the Genetic Causes of Language Dysfunction in the 1q21.1 Microduplication Syndrome. *Frontiers in Pediatrics*, **2018**, 6, 163	3.4	5
22	Gain-of-function mutations in DNMT3A in patients with paraganglioma. *Genetics in Medicine*, **2018**, 20, 1644-1651	8.1	49
21	CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. *Biomedicines*, **2018**, 6,	4.8	50
20	CRISPR-Cas9 technology: applications and human disease modelling. *Briefings in Functional Genomics*, **2017**, 16, 4-12	4.9	25

19	Efficient Recreation of t(11;22) EWSR1-FLI1 in Human Stem Cells Using CRISPR/Cas9. *Stem Cell Reports*, **2017**, 8, 1408-1420	8	35
18	Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the "safe harbor" AAVS1 locus. *Stem Cell Research*, **2017**, 21, 137-140	1.6	11
17	Modeling Cancer Using CRISPR-Cas9 Technology **2017**, 905-924		
16	CRISPR/Cas9 Technology: Applications and Human Disease Modeling. *Progress in Molecular Biology and Translational Science*, **2017**, 152, 23-48	4	10
15	The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia. *Leukemia*, **2017**, 31, 2000-2005	10.7	14
14	Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors. *Oncogene*, **2016**, 35, 125-34	9.2	21
13	Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. *Stem Cell Reports*, **2016**, 7, 602-618	8	29
12	Physical Proximity of Sister Chromatids Promotes Top2-Dependent Intertwining. *Molecular Cell*, **2016**, 64, 134-147	17.6	34
11	The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System. *Current Biotechnology*, **2015**, 3, 273-278	0.6	
10	CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling. *International Journal of Molecular Sciences* , **2015**, 16, 22151-68	6.3	17
9	An integration-defective lentivirus-based resource for site-specific targeting of an edited safe-harbour locus in the human genome. *Gene Therapy*, **2014**, 21, 343-52	4	17
8	Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. *Nature Communications*, **2014**, 5, 3964	17.4	167
7	Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy. *Cell Death and Disease*, **2013**, 4, e691	9.8	156
6	Hematologic -tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. *Cancer Research*, **2012**, 72, 4744-52	10.1	19
5	Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. *Cell Stem Cell*, **2011**, 9, 433-46	18	314
4	Non-integrative lentivirus drives high-frequency cre-mediated cassette exchange in human cells. *PLoS ONE*, **2011**, 6, e19794	3.7	15
3	A chemokine targets the nucleus: Cxcl12-gamma isoform localizes to the nucleolus in adult mouse heart. *PLoS ONE*, **2009**, 4, e7570	3.7	20
2	Somatic genome editing with the RCAS/TVA-CRISPR/Cas9 system for precision tumor modeling		1

List of Publications

1	Functional genetic characterization by CRISPR-Cas9 of two enhancers of FOXP2 in a child with speech and language impairment	1